Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: Russian Bear who wrote (494)	2/2/2000 9:16:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 666

Does this patent encompass Idec's radiolabelled MAB?

To: Russian Bear who wrote (494)	2/2/2000 9:26:00 AM
From: biowa	Read Replies (2) \| Respond to of 666

Russian Bear, Coulter Pharmaceutical(Nasdaq:CLTR - news) and SmithKline Beecham (NYSE:SBH - news) today announced that the U.S. Patent and Trademark Office has issued a composition patent relating to radiolabeled monoclonal antibodies for the treatment of B-cell lymphomas. For those looking for the patent (#6,015,542), a link: 164.195.100.11 Opinions on whether some of the language on other antibodies potentially covers Zevalin (staying away from the "I" word) (the abstract is somewhat misleading, read the claims and invention description)? biowa